Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Aromatase Inhibitors in HR+/HER2- Breast Cancer
NCT02236572Phase 2Terminated
- Sponsor
- Yale University
- Start
- Nov 2014
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in breast cancer, sponsored by Yale University. Started Nov 2014; status: terminated.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02236572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236572.